logo
logo
Cardiff Oncology, Inc.

Cardiff Oncology, Inc.

NASDAQ•CRDF
CEO: Dr. Mark Erlander Ph.D.
セクター: Healthcare
業種: Biotechnology
上場日: 2004-07-27
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
連絡先情報
11055 Flintkote Avenue, San Diego, CA, 92121, United States
858-952-7570
www.cardiffoncology.com
時価総額
$107.78M
PER (TTM)
-2.1
34.3
配当利回り
--
52週高値
$4.99
52週安値
$1.48
52週レンジ
3%
順位60Top 89.2%
2.1
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 2.1 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$120.00K-27.27%
直近4四半期の推移

EPS

-$0.17-32.00%
直近4四半期の推移

フリーCF

-$10.85M+3.79%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Onvansertib Trial Data Positive RAS-mutated mCRC trial showed 49% Confirmed ORR for 30mg dose plus SoC; combination well-tolerated across 110 patients.
Sufficient Cash Runway Total liquidity stands at $60.6M in cash and short-term investments, expected to fund operations into Q1 2027.
Quarterly Net Loss Narrowed Three-month net loss improved to $(11.3M)$ USD in 2025 from $(11.9M)$ USD in 2024 due to lower operating expenses.
Asset Base Shrinking Total assets fell $33.4M to $63.8M since year-end 2024; stockholders' equity decreased to $48.8M due to accumulated deficit.

リスク要因

Continued Capital Requirements Company expects to incur future losses requiring additional capital; uncertainty exists regarding funding availability on acceptable terms.
Operating Expenses Rising Nine-month R&D expenses rose $3.1M, driven by CRDF-004 trial costs; SG&A increased $1.8M, including severance costs.
Regulatory Agency Disruptions Potential government shutdowns or global health concerns could slow FDA reviews, significantly impacting timely regulatory submission processing.
Stock Dilution Risk Raising necessary additional funds via equity issuance may result in additional dilution for existing common stockholders.

見通し

Planning Phase 3 Trial Contingent on CRDF-004 results, Company plans to initiate CRDF-005, a Phase 3 trial with registrational intent for accelerated approval.
Advancing Multiple Programs Supporting investigator-initiated trials for onvansertib in mPDAC, relapsed SCLC, and metastatic TNBC to broaden indications.
Stock Option Vesting Ahead Unrecognized compensation cost of $11.4M related to non-vested options is expected to be recognized over 2.9 years.
Evaluating Tax Disclosure Changes Currently evaluating the impact of recently issued ASU 2023-09 regarding improvements to income tax disclosures, effective late 2024.

同業比較

売上高 (TTM)

Innate Pharma S.A.IPHA
$36.93M
-61.2%
C4 Therapeutics, Inc.CCCC
$30.11M
-10.6%
Rani Therapeutics Holdings, Inc.RANI
$1.20M
+0.0%

粗利益率 (最新四半期)

C4 Therapeutics, Inc.CCCC
100.0%
+13.4pp
Applied Therapeutics, Inc.APLT
100.0%
+0.0pp
Cardiff Oncology, Inc.CRDF
100.0%
+5842.4pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
PEPG$442.74M-2.3-84.1%9.2%
CYBN$413.02M-1.8-54.5%15.9%
FBRX$402.24M-11.0-75.6%0.0%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
-7.4%
成長鈍化
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年2月26日
|
EPS:-$0.18
|
売上高:-
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月6日|
    売上高: $120.00K-27.3%
    |
    EPS: $-0.17-32.0%
    予想通り

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年7月29日|
    売上高: $121.00K-25.8%
    |
    EPS: $-0.21-19.2%
    予想を下回る

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月8日|
    売上高: $109.00K-46.8%
    |
    EPS: $-0.20-9.1%
    予想を下回る

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月27日|
    売上高: $683.00K+40.0%
    |
    EPS: $-0.95-2.2%
    予想を下回る

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月7日|
    売上高: $165.00K+17.0%
    |
    EPS: $-0.25+13.6%
    予想を上回る

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月8日|
    売上高: $163.00K+50.9%
    |
    EPS: $-0.26+4.0%
    予想を下回る

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月2日|
    売上高: $205.00K+147.0%
    |
    EPS: $-0.22-4.3%
    予想を上回る

  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年2月29日|
    売上高: $488.00K+26.4%
    |
    EPS: $-0.93-4.5%
    予想を下回る